Trial Profile
To evaluate the efficacy of Pembrolizumab in patients with mismatch repair deficient metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2017
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results (n=19) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 16 Mar 2017 New trial record
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium